KSTATION

K-STATION is a South Korean biotechnology company specializing in the development of exosome-based cancer immunotherapies. Spun off from the Korea Institute of Science and Technology (KIST) in 2021, the company utilizes a proprietary platform to engineer exosomes for targeted drug delivery and immune system modulation. Their lead programs focus on creating exosome-based cancer vaccines and immune checkpoint inhibitors designed to treat various solid tumors. By leveraging the natural biocompatibility of exosomes, K-STATION aims to provide more effective and less toxic alternatives to traditional cancer treatments. The company's technology platform allows for the precise loading of therapeutic agents and the modification of exosome surfaces to enhance tumor targeting. K-STATION is currently in the pre-clinical stage, advancing its pipeline toward first-in-human clinical trials.